| TABLE 3. Clinical efficacy of goserelin plus tamoxifen versus
goserelin alone in 318 premenopausal patients with advanced breast cancer
* |
|
|
Randomized Treatment
|
|
|
Goserelin
alone
(n=159)
|
Goserelin plus Tamoxifen (n=159)
|
p value
|
|
Objective response (CR + PR), n(%)
|
50 (31)
|
60 (38)
|
0.24
|
|
complete response
|
8 (5)
|
12 (8)
|
|
|
partial response
|
42 (26)
|
48 (30)
|
|
|
No change, n (%)
|
51 (32)
|
42 (26)
|
|
|
Progression, n (%)
|
49 (31)
|
47 (30)
|
|
|
Median duration of response, weeks (range)
|
59 (12-216)
|
88 (8-196)
|
|
|
Median time to first progression, weeks (range)
|
23 (0-216)
|
28 (0-196)
|
0.03
|
|
Median survival, weeks (range)
|
127 (0-303)
|
140 (0-298)
|
0.25
|
|
| CR, complete response; PR, Partial response |
| (From ref. 44, reproduced with permission
of Elsevier Science Ltd). |
| Back to Chapter
|